Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nippon Shinyaku Co., Ltd. (4516.T)
Kyoto, JP
Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +1.25% | -17.14% | -15.03% | +19.69% | -23.76% | +23.83% | -33.56% | -41.65% | -22.16% | +346.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 3 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.6% Q1'26: +12.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-8.7% Q1'26: -3.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.7% Q1'26: +33.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.3% ★ Q1'26: +6.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.4% ★ Q1'26: +4.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.06× ★ Q1'26: 0.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 7 EPS Ana. |
Mar 2027 5 Rev. Ana. 2 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
79.99B
est: 81.00B (-1.2%)
|
84.21B
est: 85.90B (-2.0%)
|
98.78B
est: 99.28B (-0.5%)
|
101.45B
est: 103.10B (-1.6%)
|
114.72B
est: 112.47B (+2.0%)
|
116.64B
est: 117.99B (-1.1%)
|
121.89B
est: 123.15B (-1.0%)
|
137.55B
est: 137.91B (-0.3%)
|
144.18B
est: 142.02B (+1.5%)
|
148.26B
est: 150.37B (-1.4%)
|
160.23B
est: 159.54B (+0.4%)
|
169.63B
168.33B – 170.70B
+6.3% YoY
|
185.95B
180.19B – 195.13B
+9.6% YoY
|
182.35B
167.53B – 205.45B
-1.9% YoY
|
207.24B
206.72B – 207.76B
+13.6% YoY
|
294.00B
277.62B – 319.68B
+41.9% YoY
|
| EBITDA |
11.23B
est: 20.99B (-46.5%)
|
11.00B
est: 22.26B (-50.6%)
|
17.93B
est: 25.73B (-30.3%)
|
19.85B
est: 26.72B (-25.7%)
|
24.06B
est: 29.15B (-17.4%)
|
25.14B
est: 30.58B (-17.8%)
|
30.54B
est: 31.92B (-4.3%)
|
32.89B
est: 35.74B (-8.0%)
|
34.29B
est: 36.81B (-6.8%)
|
36.41B
est: 36.74B (-0.9%)
|
42.78B
est: 38.98B (+9.7%)
|
41.45B
41.13B – 41.71B
+6.3% YoY
|
45.44B
44.03B – 47.68B
+9.6% YoY
|
44.56B
40.94B – 50.20B
-1.9% YoY
|
50.64B
50.51B – 50.77B
+13.6% YoY
|
71.84B
67.84B – 78.11B
+41.9% YoY
|
| EBIT |
8.56B
est: 18.14B (-52.8%)
|
8.55B
est: 19.24B (-55.6%)
|
15.28B
est: 22.24B (-31.3%)
|
17.08B
est: 23.09B (-26.0%)
|
20.65B
est: 25.19B (-18.1%)
|
21.67B
est: 26.43B (-18.0%)
|
26.14B
est: 27.59B (-5.3%)
|
28.30B
est: 30.89B (-8.4%)
|
29.25B
est: 31.81B (-8.1%)
|
31.39B
est: 31.37B (+0.0%)
|
36.76B
est: 33.29B (+10.4%)
|
35.39B
35.12B – 35.61B
+6.3% YoY
|
38.80B
37.59B – 40.71B
+9.6% YoY
|
38.05B
34.95B – 42.86B
-1.9% YoY
|
43.24B
43.13B – 43.35B
+13.6% YoY
|
61.34B
57.92B – 66.70B
+41.9% YoY
|
| Net Income |
5.88B
est: 6.18B (-4.7%)
|
6.34B
est: 6.10B (+4.0%)
|
11.75B
est: 11.52B (+2.0%)
|
12.95B
est: 13.75B (-5.8%)
|
16.30B
est: 15.52B (+5.0%)
|
16.87B
est: 17.04B (-1.0%)
|
19.54B
est: 20.24B (-3.5%)
|
24.99B
est: 23.11B (+8.1%)
|
22.81B
est: 23.31B (-2.1%)
|
25.85B
est: 27.37B (-5.5%)
|
32.56B
est: 30.55B (+6.6%)
|
27.66B
26.53B – 29.64B
-9.5% YoY
|
25.66B
25.28B – 26.03B
-7.2% YoY
|
15.81B
9.51B – 20.65B
-38.4% YoY
|
16.68B
15.84B – 26.29B
+5.5% YoY
|
41.10B
38.12B – 45.76B
+146.5% YoY
|
| SGA |
20.92B
est: 18.94B (+10.4%)
|
21.56B
est: 20.09B (+7.3%)
|
23.37B
est: 23.21B (+0.7%)
|
23.76B
est: 24.11B (-1.4%)
|
26.07B
est: 26.30B (-0.9%)
|
27.47B
est: 27.59B (-0.4%)
|
28.84B
est: 28.80B (+0.2%)
|
34.82B
est: 32.25B (+8.0%)
|
33.87B
est: 33.21B (+2.0%)
|
33.96B
est: 36.18B (-6.2%)
|
36.99B
est: 38.39B (-3.6%)
|
40.82B
40.50B – 41.07B
+6.3% YoY
|
44.74B
43.36B – 46.95B
+9.6% YoY
|
43.88B
40.31B – 49.43B
-1.9% YoY
|
49.87B
49.74B – 49.99B
+13.6% YoY
|
70.74B
66.80B – 76.92B
+41.9% YoY
|
| EPS |
87.26
est: 91.66 (-4.8%)
|
94.10
est: 90.50 (+4.0%)
|
174.42
est: 170.98 (+2.0%)
|
192.31
est: 204.07 (-5.8%)
|
242.03
est: 230.43 (+5.0%)
|
250.41
est: 252.93 (-1.0%)
|
290.11
est: 300.47 (-3.4%)
|
370.97
est: 343.08 (+8.1%)
|
338.70
est: 369.22 (-8.3%)
|
383.82
est: 406.31 (-5.5%)
|
483.40
est: 470.34 (+2.8%)
|
409.45
393.67 – 439.81
-12.9% YoY
|
380.74
375.17 – 386.30
-7.0% YoY
|
234.82
141.16 – 306.35
-38.3% YoY
|
286.50
235.08 – 390.03
+22.0% YoY
|
609.80
565.63 – 679.04
+112.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.25% | 958.1K | 0.58% |
| 2 | Vident International Equity Strategy ETF VIDI | 0.14% | 558.2K | 0.61% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.10% | 575.1K | 0.58% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.09% | 243.3K | 0.50% |
| 5 | Vanguard Global Value Equity Active ETF VVLU.AX | 0.09% | 825.6K | 0.28% |
| 6 | Vanguard Global Value Factor ETF VVL.TO | 0.08% | 468.6K | 0.38% |
| 7 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.08% | 348.1K | 0.48% |
| 8 | Schwab Fundamental International Small Company Index ETF FNDC | 0.08% | 2.39M | 0.39% |
| 9 | WisdomTree International SmallCap Dividend Fund DLS | 0.07% | 714.6K | 0.58% |
| 10 | Dimensional - International Small Cap Value ETF DISV | 0.07% | 3.16M | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hayato Wada | Corporate Officer & Department Manager of Kansai Business Office | — | — |
| Hideyuki Fujii | Accounting & Finance Department Manager | — | male |
| Hitomi Kimura | Director of Resource Procurement, Production & Assurance & Director | — | female |
| Hitoshi Ishizawa | GM of Functional Food Division & Director | — | male |
| Katsumi Noda | Corporate Officer & Department Manager of Tokyo Business Office | — | — |
| Kazuyuki Iwata | Director of Sales and Marketing & Director | — | — |
| Kazuyuki Yamate | Corporate Officer & Head of Digital Transformation Div. | — | — |
| Keiichi Kuwano | GM of Research & Development and Director | — | — |
| Manabu Beppu | Corporate Officer and Head of R & D Planning and Administration Div. | — | — |
| Masaya Toda | Head of Licensing & Alliance Division and Corporate Officer | — | — |
| Takanori Edamitsu | Head of Business Management & Sustainability and Director | — | male |
| Takashi Takaya | GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4516.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
